The Expression of p-STAT3 in Stage IV Melanoma: Risk of CNS Metastasis and Survival

Oncotarget

Volumn 3, Issue 3, 2012, Pages 336-344

  Lee, Ian ^a   Fox, Patricia S ^a   Ferguson, Sherise D ^a   Bassett, Roland ^a   Kong, Ling Yuan ^a   Schacherer, Christopher W ^a   Gershenwald, Jeffrey E ^a   Grimm, Elizabeth A ^a   Fuller, Gregory N ^a   Heimberger, Amy B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CNS metastasis; Melanoma; P stat3; Prognosis

Indexed keywords

STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; COHORT ANALYSIS; FEMALE; HUMAN; MALE; MELANOMA; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING; RISK FACTOR; SKIN TUMOR; TISSUE MICROARRAY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; COHORT STUDIES; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RISK FACTORS; SKIN NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84865677558     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.475     Document Type: Article

References (46)

1. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Jr., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27(36):6199-6206.
2. Wen PY, Black PM and Loeffler JS. (2001). Treatment of metastatic brain cancer. In: DeVita VTJ, Hellman S and Rosenberg SA, eds. Principles and Practice of Oncology. (Philadelphia: Lippincott Williams & Wilkins).
3. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P and Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004; 22(14):2865-2872.
4. Houghton AN, Coit DG, Daud A, Dilawari RA, Dimaio D, Gollob JA, Haas NB, Halpern A, Johnson TM, Kashani-Sabet M, Kraybill WG, Lange JR, Martini M, Ross MI, Samlowski WE, Sener SF, et al. Melanoma. J Natl Compr Canc Netw. 2006; 4(7):666-684.
5. De la Monte SM, Moore GW and Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res. 1983; 43(7):3427-3433.
6. Patel JK, Didolkar MS, Pickren JW and Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg. 1978; 135(6):807-810.
7. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L and Rosenberg SA. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999; 17(7):2105-2116.
8. Sampson JH, Carter JH, Jr., Friedman AH and Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998; 88(1):11-20.
9. Chiarion-Sileni V, Guida M, Ridolfi L, Romanini A, Del Bianco P, Pigozzo J, Brugnara S, Colucci G, Ridolfi R and De Salvo GL. Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. Br J Cancer. 2011; 104(12):1816-1821.
10. Masamune A, Satoh M, Kikuta K, Suzuki N and Shimosegawa T. Activation of JAK-STAT pathway is required for platelet-derived growth factor-induced proliferation of pancreatic stellate cells. World J Gastroenterol. 2005 11(22):3385-3391.
11. Huang S. Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res. 2007; 13(5):1362-1366.
12. Yu H and Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 2004; 4(2):97-105.
13. Winston LA and Hunter T. JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase/ mitogen-activated protein kinase by growth hormone. J Biol Chem. 1995 270(52):30837-30840.
14. Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, Xie K, Sawaya R and Huang S. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res. 2006; 66(6):3188-3196.
15. Bao JJ, Fokt I, Szymanski S and Priebe W. Inhibition of constitutively active STAT3 by WP1066 suppresses proliferation and induces apoptosis in pancreatic cancer cells. Clin Cancer Res. 2005; 11(24):9026S-9027S.
16. Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, Takeda J and DiGiovanni J. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest. 2004 (PMCID: PMC514583); 114(5):720-728.
17. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, Kondo S, Priebe W and Kondo Y. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene. 2007; 26(17):2435-2444.
18. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF and Grandis JR. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A. 2003; 100(7):4138-4143.
19. Tang GS, Cai JM, Ni J, Xiang YS, Cui JG, Zhu D and Dong JR. Effects of STAT3 antisense oligodeoxynucleotides on apoptosis and proliferation of mouse melanoma cell line B16. Ai Zheng. 2006; 25(3):269-274.
20. Xi S, Gooding WE and Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene. 2005; 24(6):970-979.
21. Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, Dalton W, Jove R and Yu H. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. 1999 59(20):5059-5063.
22. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C and Darnell JE, Jr. Stat3 as an oncogene.[erratum appears in Cell 1999 Oct 15;99(2):239]. Cell. 1999; 98(3):295-303.
23. Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I and Bromberg JF. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci U S A. 2004; 101(29):10602-10607.
24. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mule J, Kerr WG, Jove R, Pardoll D and Yu H. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005; 11(12):1314-1321.
25. Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Priebe W, Sawaya R, Lang FF and Heimberger AB. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther. 2010; 9(1):67-78.
26. Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R and Huang S. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene. 2004; 23(20):3550-3560.
27. Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong LY, Fuller GN, Hiraoka N, Priebe W, Sawaya R and Heimberger AB. The incidence, correlation with tumorinfiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res. 2008; 14(24):8228-8235.
28. Kaplan EL and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53:457-481.
29. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50(3):163-170.
30. Birner P, Toumangelova-Uzeir K, Natchev S and Guentchev M. STAT3 tyrosine phosphorylation influences survival in glioblastoma. J Neurooncol. 2010; May 9 [e-pub ahead of print].
31. Martinez SR and Young SE. A rational surgical approach to the treatment of distant melanoma metastases. Cancer Treat Rev. 2008; 34(7):614-620.
32. Wang W, Edington HD, Rao Un, et al. Modulation of signal trnasducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha 2b. Clin Cancer Res 2007;13:1523-31.
33. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, Popoff S, Nutt CL, Louis DN, Cairncross JG, Gilbert MR, Phillips HS, Mehta MP, Chakravarti A, Pelloski CE, Bhat K, et al. A multigene predictor of outcome in glioblastoma. Neuro Oncol. 2010; 12(1):49-57.
34. de Tayrac M, Aubry M, Saikali S, Etcheverry A, Surbled C, Guenot F, Galibert MD, Hamlat A, Lesimple T, Quillien V, Menei P and Mosser J. A 4-gene signature associated with clinical outcome in high-grade gliomas. Clin Cancer Res. 2011; 17(2):317-327.
35. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001; 19(16):3622-3634.
36. Pollock BE, Brown PD, Foote RL, Stafford SL and Schomberg PJ. Properly selected patients with multiple brain metastases may benefit from aggressive treatment of their intracranial disease. J Neurooncol. 2003; 61(1):73-80.
37. Sosman JA, Moon J, Tuthill RJ, Warneke JA, Vetto JT, Redman BG, Liu PY, Unger JM, Flaherty LE and Sondak VK. A phase 2 trial of complete resection for stage IV melanoma: Results of Southwest Oncology Group Clinical Trial S9430. Cancer. 2011.
38. Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer GE, Jr., Sampson JH, Priebe W and Heimberger AB. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res. 2008; 14(18):5759-5768.
39. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, Bellucci R, Raderschall E, Canning C, Soiffer RJ, Frank DA and Ritz J. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006; 108(5):1571-1579.
40. Knol AC, Nguyen JM, Quereux G, Brocard A, Khammari A and Dreno B. Prognostic value of tumor-infiltrating Foxp3+ T-cell subpopulations in metastatic melanoma. Exp Dermatol. 2011; 20(5):430-434.
41. Miracco C, Mourmouras V, Biagioli M, Rubegni P, Mannucci S, Monciatti I, Cosci E, Tosi P and Luzi P. Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma. Oncol Rep. 2007; 18(5):1115-1122.
42. Fujiwara Y, Komohara Y, Kudo R, Tsurushima K, Ohnishi K, Ikeda T and Takeya M. Oleanolic acid inhibits macrophage differentiation into the M2 phenotype activation of STAT3. Oncol Rep. 2011; 26(6):1533-1537.
43. Ohnishi K, Komohara Y, Sakashita N, Iyama K, Murayama T and Takeya M. Macrophages in Langerhans cell histiocytosis are differentiated toward M2 phenotype: their possible involvement in pathological processes. Pathol Int. 2010; 60(1):27-34.
44. Takaishi K, Komohara Y, Tashiro H, Ohtake H, Nakagawa T, Katabuchi H and Takeya M. Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation. Cancer Sci. 2010; 101(10):2128-2136.
45. Chen P, Huang Y, Bong R, Ding Y, Song N, Wang X, Song X and Luo Y. Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in both paracrine and autocrine manners. Clin Cancer Res. 2011.
46. Bronkhorst IH, Ly LV, Jordanova ES, Vrolijk J, Versluis M, Luyten GP and Jager MJ. Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci. 2011; 52(2):643-650.